IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint — Sep 5, 2026Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.

Jared Kim Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.

Lancet study finds 45% of dementia cases could be prevented despite diagnosis delays — Sep 6, 2026A Lancet study suggests as many as 45% of dementia cases could be prevented or delayed through modifiable risk factors such as smoking, diet, exercise, hearing/vision care, and social engagement, reinforcing the idea that heart and brain health are tightly linked. Meanwhile, reports from the UK highlight long delays in dementia diagnosis and the strain on families, even as a Phase III trial explores biomarker-based prevention before symptoms appear, underscoring the need for scalable diagnostic infrastructure and timely support.

Zydus Lifesciences plans Phase III Desidustat trial sickle cell ICMR — Jul 23, 2026Zydus Lifesciences has received regulatory approval to initiate a 203-day Phase III trial of Desidustat for sickle cell disease in collaboration with ICMR, enrolling 164 patients to assess efficacy and safety of the oral tablet. The move follows successful Phase II results and US FDA Orphan Drug Designation, underscoring a public-private effort to address India's substantial SCD burden.

AstraZeneca Ends Phase III Lung Cancer Trial — Aug 17, 2026AstraZeneca reports a setback as its Phase III trial of volrustomig plus chemotherapy in PD-L1 negative metastatic non-small cell lung cancer is halted after an independent data review found it unlikely to meet primary endpoints, while another late-stage study in cervical cancer and other indications continues. In a positive contrast, AZN and partners SAFFRON showed that Tagrisso combined with Orpathys significantly improved progression-free and overall survival, underscoring a mixed near-term outlook but ongoing strength in its immuno-oncology pipeline.

IJRChina Charges Back Into The Oil Market As Hormuz Chaos Sends Crude Toward $110Paris Apodaca · 5 min · 1h

Commentary: Dr. Fauci: It’s ‘Still Not OK’ for Vaccinated Americans To Eat and Drink IndoorsReporting — Apr 12, 2021From the very beginning, I was one of the people most excited about the coming COVID-19 vaccines. I have mentioned several times that I was a participant in Moderna’s Phase III trial, and the thought that I contributed…

YourlistRankingMost Influential Women in World HistoryFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.1379 votes · 26 candidates

Hutchmed Secures NMPA Approval for ATLED ICCHealth — Aug 28, 2026HUTCHMED announced conditional NMPA approval for ATLED (fanregratinib), an FGFR1/2/3 inhibitor, to treat adult patients with advanced FGFR2-fusion intrahepatic cholangiocarcinoma after prior systemic therapy, with China commercialization planned under the ATLED name. The pivotal data show a 42.5% objective response rate, rapid onset, and durable disease control, supporting a Phase IIIb confirmatory program alongside ongoing commercialization in China.